Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
-
Summary:
Pfizer (PFE - Free Report) announced that the FDA has granted approval to its 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults. The vaccine will be marketed by the brand name of Prevnar 20.
Prevnar 20 includes all the 13 serotypes contained in Pfizer’s popular 13-valent pneumococcal conjugate vaccine, Prevnar 13 along with seven additional serotypes, which account for 40% of pneumococcal disease cases and deaths in theUnited States. This way it covers more serotypes responsible for the majority of invasive pneumococcal disease and pneumonia than any other marketed vaccine or those in clinical development.
The biologics license application (BLA) seeking approval for Prevnar 20 was based on data from three phase III studies, which ...
Read Full News: https://www.zacks.com/stock/news/1680444/pfizer-pfe-gets-fda-nod-for-pneumococcal-vaccine-prevnar-20